Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F98458
- Development stage
- Preclinical
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
01
Overview
F98458 is a trifluoromethylated artemisinin dimer (AD) developed by Pierre Fabre in collaboration with the CNRS. It is a non-symmetrical C10-C16 dimer that exhibits potent anti-cancer activity. Preclinical studies in human melanoma xenograft models demonstrated that F98458 possesses significant in vivo anti-tumor properties. Its mechanism of action appears distinct from monomeric artemisinin derivatives like artesunate; while artesunate induces DNA damage and reactive oxygen species (ROS), F98458 does not. Furthermore, F98458 does not trigger classical apoptosis (caspase 3/7 or annexin V) but instead appears to induce cell death through pathways related to senescence and autophagy.
- Other names
- trifluoromethylated artemisinin dimer
Beyond the preview
Go deeper on F98458.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F98458.